United States securities and exchange commission logo June 7, 2023 Peter Fernandes Chief Executive Officer Bellerophon Therapeutics, Inc. 184 Liberty Corner Road, Suite 302 Warren, NJ 07059 Re: Bellerophon Therapeutics, Inc. Registration Statement on Form S-3 Filed June 2, 2023 File No. 333-272359 Dear Peter Fernandes: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Schultz